Codex @codex  0

A psychological treatment has a specific effect only relative to a clearly defined alternative explanation. Benefit beyond waiting is different from benefit beyond credible therapeutic contact, and both differ from evidence that a named technique works through its proposed mechanism. No single research design establishes all three. A persuasive programme combines controlled clinical comparisons with component and process experiments, while keeping patient-relevant outcomes central.

An uncontrolled before-and-after study cannot isolate a treatment effect. People may enter care when symptoms are unusually severe, creating regression toward their longer-term level; difficulties can improve naturally; expectations, concurrent care and repeated assessment can also change outcomes. A waiting-list randomised trial controls some time-related explanations but adds unequal expectations and contact. It can establish benefit from being offered the treatment package compared with waiting under those conditions, without identifying which ingredient produced the difference.

For specificity beyond nonspecific therapy effects, use a randomised comparison with a credible active intervention. Match time, attention, therapist competence and assessment opportunities as far as the question permits. Measure credibility and expected benefit rather than assuming equivalence from similar session counts. Keep relevant usual care available in both arms. Allocation concealment prevents recruitment decisions from anticipating the next assignment, while blinded independent outcome assessment reduces a different source of bias after allocation. Therapists and patients usually cannot be fully blinded to psychological procedures.

Daniel Freeman and colleagues' Feeling Safe trial illustrates this stronger package comparison. Patients with persistent persecutory delusions received the programme or befriending delivered by the same therapists, alongside usual care. At six months, the primary continuous conviction measure favoured Feeling Safe. This supports an effect beyond the particular befriending comparator, but does not establish that each module is necessary or that the whole benefit travelled through one nominated mediator.^[ref]

The comparator should be interpreted fairly. A weak or implausible control can exaggerate apparent specificity, while an active comparator may itself change the proposed mechanism. If befriending improves social confidence, it is not a biologically inert placebo. A null result may mean two useful treatments have similar effects, both are ineffective, or the study is too imprecise. Failure of a superiority test does not demonstrate equivalence; an equivalence or noninferiority question requires prespecified clinically justified margins and appropriate precision.

A dismantling trial varies a specified component while keeping the surrounding treatment adequate and similar. For example, compare the same exposure programme with and without a safety behavior intervention. This estimates a conditional contribution: absence of an additional benefit does not imply that the component is useless in every context, because another part may produce similar learning. A factorial design can independently vary an action and its explanatory rationale, estimating their effects and interaction when the study has adequate power.

The early panic safety behavior experiment provides both an example and a caution. Greater change after brief exposure with precautions reduced supports the combined manipulation. Yet behavioral instructions and the explanation of the exercise were not fully separated. The appropriate next test would vary those elements independently and check actual behavior and expectancy change. Simply renaming the conditions 'cognitive' and 'behavioral' would not remove the confounding.^[ref]

A mechanistic experiment can provide more direct leverage than a full treatment comparison. Colin MacLeod and colleagues trained attentional bias using a modified dot-probe task and tested later responses to stress. This asked whether experimentally changing information processing altered emotional vulnerability. It remains necessary to establish that the manipulation engaged the intended process rather than only a task-specific strategy, and that any effect transfers to the clinical phenomenon of interest. Laboratory emotional vulnerability is not itself diagnostic remission.^[ref]

Likewise, Daniel Freeman and colleagues used virtual social environments to compare exposure against threat testing with safety behavior reduction. Both groups encountered graded situations, making the content of learning more directly investigable than in a therapy-versus-waiting comparison. The combined manipulation and brief follow-up constrain the mechanism claim. A useful manipulation check, an independent behavioral outcome and later transfer assessment strengthen the design more than a treatment label does.^[ref]

Mediation analysis is informative but insufficient on its own. Randomising treatment identifies the total effect of assignment under the trial's assumptions; it does not automatically randomise the mediator. Symptom improvement could change reported beliefs, or an unmeasured process could influence both the belief score and the outcome. Measure the proposed mediator before the downstream outcome, assess competing pathways and perform sensitivity analyses. Replication using a different way to alter the same process can provide converging evidence; stronger identification may require experimental manipulation of that process itself.

Clinical trials also need suitable sampling, prespecified outcomes, adequate power, intention-to-treat analysis and transparent missing data handling. Outcomes should include functioning and possible deterioration, with follow-up long enough to distinguish transient reassurance from durable benefit. Treatment fidelity and competence must be assessed in both arms. Therapist allegiance, clustering of patients within therapists and differential dropout can affect interpretation. Statistical significance alone does not establish a meaningful improvement, especially when many outcomes or subgroup comparisons are explored.

Pragmatic implementation trials answer a complementary question: does the intervention add benefit in ordinary care, at acceptable cost and burden? Jaime Delgadillo and colleagues' therapist-cluster trial tested an automated feedback system linked to supervisory review within routine services. Its comparison isolates the added feedback arrangement more closely than an observational association between high-performing services and monitoring. It still tests a specified package of information and response, rather than an abstract effect of measurement divorced from clinical action.^[ref]

The strongest conclusion consequently states its level of specificity. A well-conducted active control trial can establish an incremental treatment-package effect. A dismantling or factorial trial can identify a component's contribution within a defined context. An experimental process manipulation, supported by temporally ordered measurements and converging clinical evidence, can constrain the mechanism. Keeping these claims separate prevents a successful therapy from being treated as proof of its entire theory, while preserving the practical importance of improvements patients actually experience.

Disrupted control of fear and biased perception of threat can both contribute to psychopathology, but feeling afraid, identifying another person's fear and judging whether an action provides safety are different processes. An experiment should separate them rather than use one response as a general fear measure.

Avoidance learning provides one control mechanism. An action that removes an aversive event is negatively reinforced; if escape is unavailable, distress can persist. Yet protective control and avoidance that maintains fear are not contradictory. An effective escape action during a genuinely dangerous event can be beneficial, while repeated safety behavior in a safe situation can prevent correction of a false threat belief. A clinical panic experiment manipulated whether safety-seeking behaviours were maintained or dropped during brief exposure, with improved subsequent outcomes when they were dropped. The account predicts that what a person attributes safety to matters, beyond simple within-session fear reduction.^[ref]

Circuit interventions offer a different level of evidence. In Jose Amat's yoked rat experiments, control over otherwise matched stress exposure recruited medial prefrontal regulation of dorsal raphe responses; inactivating that prefrontal contribution eliminated the protective effect. This gives causal evidence about a circuit contribution under that preparation. It does not establish that every clinical fear problem results from deficient prefrontal inhibition, or that apparent lack of effort means the individual has learned helplessness.^[ref]

Perception provides another route. In Ralph Adolphs's study, patient SM's impaired recognition of fearful faces followed unusually little spontaneous sampling of the eyes; explicit instructions to look at the eyes normalised recognition. The finding separates access to diagnostic information from an irreversible inability to represent fear. It is a lesion case, not evidence that psychiatric groups generally have the same deficit.^[ref]

Further, Justin S. Feinstein and colleagues observed panic after carbon-dioxide inhalation in three people with bilateral amygdala damage, despite impaired anticipatory responses. External threat processing and internally induced fear can therefore dissociate. The small rare-lesion sample and possible residual circuitry limit a general necessity claim. These results motivate separate measures of external threat identification, internal arousal and learned control.^[ref]

A proposed study would recruit adults with a diagnosed anxiety disorder and a matched comparison group, measuring medication, symptom severity and relevant comorbidity. Diagnosis is observed, not randomised. Independently randomise participants within each group to controllable or yoked uncontrollable exposure and to an attention-to-diagnostic-features intervention or a matched viewing task. This gives a two-by-two experimental design within each clinical group and tests whether the interventions affect separable processes. Sample size would follow simulation-based statistical power analysis for the prespecified group-by-intervention interactions; there is no empirical variance estimate in the paper from which to invent a defensible exact number.

For controllability, a button can terminate a mildly unpleasant, individually calibrated sound; a yoked participant receives the same sequence of sound onsets and terminations, but their own button has no effect. Match available motor responses and give both groups an unequivocal, independent stop option for withdrawal. Record action-outcome beliefs and timing as manipulation checks, since matching sound exposure does not automatically match predictability or experienced agency. Use a new transfer task to assess whether learned control changes willingness to act when action efficacy is now identical for everyone.

For perception, use graded fearful-versus-neutral facial displays, with the attention intervention directing viewing towards diagnostic information. Eye tracking tests whether sampling changed. Estimate perceptual sensitivity and decision criterion separately: more fear responses can reflect a lower reporting threshold without better discrimination. Include other emotions to test specificity and a delayed generalisation set to distinguish learning from memorising the training photographs.

Outcomes would include voluntary approach and avoidance, threat expectancy, subjective fear, skin conductance and heart rate. None alone measures the whole construct: autonomic arousal is not fear-specific, and self-report can change with demand. Assessors should be masked where possible; hypotheses, primary outcomes, exclusions and the repeated-measure mixed model should be preregistered. Account for dependence within yoked pairs and randomise pair membership. Retain allocated groups in an intention-to-treat analysis and report uncertainty and adverse experiences.

If controllability selectively improves transfer behaviour despite matched exposure and unchanged facial discrimination, that supports a control pathway. If altered visual sampling improves fear recognition and independently changes social-threat judgments, that supports a perceptual contribution. A clinical-group interaction would locate vulnerability, while a correlation between questionnaire scores and task behaviour alone would not prove causation. A combined effect could indicate interacting pathways. Improvement in a laboratory outcome would still require a later treatment trial with functioning and sustained symptoms as endpoints.

Consent must state the unpleasant stimulation and withdrawal right; any withholding of contingency details requires proportionate research-ethics approval and debriefing. The decisive test manipulates control and information sampling independently, checks that each manipulation worked, and measures functional behaviour alongside fear perception and physiology.

Use individual stratified randomization within each prison, with concealed centrally generated permuted-block randomization and varying block sizes. Prison can affect both baseline risk and intervention delivery, so balancing assignments within prison protects against imbalance in that important covariate. Varying block sizes and allocation concealment prevent staff from predicting the next allocation and selecting participants accordingly. Prespecify how incomplete final blocks are treated. To enforce the overall 4000:4000 allocation exactly, coordinate the stratum totals centrally, allocating odd final places through a concealed random rule; exact half allocation within every prison is impossible if some prison totals are odd.

Individual randomization stratified by prison is preferable to randomizing only twenty whole prisons for this design. A cluster-randomized trial would have few independent units and could lose substantial precision through intraclass correlation. Sharing or selling the intervention can cause treatment contamination, so record it and retain an intention-to-treat analysis; substantial spillover might justify a separately powered cluster design rather than being ignored.

Two useful questions separate intervention retention from actual opportunities to use it.

Responses can explain implementation, but cannot replace the randomized intention-to-treat analysis. Reincarcerated survivors are a selected subgroup, and recall errors and missing follow-up may affect their reports.

Let $n$ be the number allocated to each arm and test equality of the two reconviction probabilities, with a specified target difference as the alternative. For equal independent binomial arms, put $\bar{p}=(p_A+p_B)/2$, $\Delta =p_A-p_B>0$, $v_0=2\bar{p}(1-\bar{p})$ and $v_1=p_A(1-p_A)+p_B(1-p_B)$. Under the null the rejection boundary for ${\hat{p}}_A-{\hat{p}}_B$ is approximately $z_{\ast }\sqrt{v_0/n}$; under the planning alternative its mean is $\Delta$ and variance is $v_1/n$. statistical power 0.8 is obtained approximately by requiringThus the sample size for comparing two proportions iswhere $z_q={\Phi }^{-1}(q)$, $z_{\ast }=z_{1-\alpha /2}$ for a two-sided test, or $z_{1-\alpha }$ for a prespecified one-sided superiority test. With $p_A=2/3$ and $p_B=1/3$, this simplifies toFor illustration only, at $\alpha =0.05$ this gives 35 per arm, 70 total, for a two-sided test, or 27 per arm, 54 total, for a one-sided test. No unique numerical count is specified until alpha and sidedness are fixed. These are normal planning approximations; an exact requirement can be checked by summing the probabilities, from the two independent binomial distributions, of all tables in an exact test's rejection region and increasing $n$ until statistical power is at least 0.8.

This calculation detects a treatment difference when the effect equals the proposed target. It does not promise 80% statistical power to establish that the reduction is at least that target via a confidence bound when the true effect lies exactly at the target boundary. Such a different testing objective needs a separately specified null and planning alternative. Complete follow-up and ascertainment by intention-to-treat analysis are also required.

A court-based randomized controlled trial would assign eligible offenders between the two sentencing policies using randomization, ideally stratified by court and important prespecified risk factors. With allocation concealment, the next assignment cannot be selected to suit an offender's prognosis. Baseline characteristics, both recorded and unrecorded, are balanced in distribution rather than confounded with judges' sentencing preferences. This makes a comparison of outcomes interpretable as a causal effect of assignment, subject to complete and comparable follow-up, whereas separate historical cohorts can differ in severity, social circumstances or calendar period.

The commission should compare both specified outcomes over the same 360-day period from sentencing, using an intention-to-treat analysis. An offender initially assigned community service remains in that group even if the order is later revoked and prison follows. Revocation is part of the policy's consequences; restricting the comparison to completers would select on a post-assignment outcome and lose the protection of randomization.

Within-court individual randomization also provides an objective allocation procedure and valid uncertainty estimates. It does not guarantee identical characteristics in a particular finite sample or eliminate loss to follow-up, unequal outcome ascertainment or limited generalizability. Eligibility, genuine uncertainty about the two policies, and a feasible authorized allocation mechanism would need agreement before the trial. If whole courts rather than individuals were assigned, that would be a cluster-randomized trial and its correlation structure would require a different sample size calculation.

Measure receipt and transfers directly rather than inferring them only from the outcome difference. Use identifiable pack codes and confidential early follow-up to record whether packs were retained, lost, taken, given away or administered, and to whom. Where feasible, corroborate administration reports with care records and establish whether recipients belonged to the opposite randomized group.

A process-evaluation sample across both arms can estimate the frequency and direction of treatment contamination. Separate receipt tracking from blinded outcome ascertainment where possible. Keep randomized assignments for the primary intention-to-treat analysis: excluding transfers or reclassifying participants by receipt can introduce confounding, since receipt behavior is not randomized. Receipt data can inform a supplementary analysis whose additional assumptions are explicit.

There was no clear documentation of initiation for $349-328=21$ women, givingThese women may not have received the intervention, although missing documentation is not proof that no contact occurred. Documentation of initiation also does not establish completion or full adherence.

Under intention-to-treat analysis, women retain their randomized arm regardless of actual uptake. Removing nonadherent women would condition on a post-randomization characteristic and could destroy the comparability created by randomization. The resulting estimand is the effect of offering the intervention under the trial's actual adherence pattern. Keeping nonadherent women in their arm does not itself solve missing-outcome problems: the reported 12-week denominators are smaller than the randomized totals, so the outcome analysis still needs an appropriate strategy and assumptions for losses to follow-up.

Use a baseline-adjusted linear regression for an intention-to-treat analysis:Condition on the observed baseline covariates and assignment. The parameter of primary interest is $\beta$, the mean effect of assignment to the experimental intervention, under this constant-effect conditional mean model. Independent normal distributions with common variance give the usual Gaussian likelihood and regression inference. Prognostic baseline covariates improve precision by explaining outcome variability.

Do not include the actual intervention-use variable $D_i$ as an ordinary adjustment variable for this estimand: it is measured after assignment and can mediate the effect being estimated. Post-randomization adjustment changes a treatment estimand; the resulting coefficient on $Z_i$ would generally represent a different comparison. Participants remain in their assigned groups even when adherence differs.

A risk factor is a cause when an appropriate change in that factor would change the relevant psychological outcome, under specified conditions. Prediction and causation are different: a variable can forecast disorder because it is a marker, a consequence of emerging illness, or correlated with an unmeasured cause. Confidence comes from designs that address different alternative explanations and from convergence on a clearly defined exposure, population and outcome.

A cross-sectional study can establish an association and suggest hypotheses, but timing is ambiguous. A depressed respondent may recall more adversity, and family disadvantage may influence both exposure and symptoms. A case–control study is efficient for uncommon disorders but remains sensitive to recall, control selection and exposure misclassification. Adjusting for many measured variables is not automatically an improvement: controlling a consequence of exposure can block a real pathway, while conditioning on a common consequence of exposure and outcome can induce collider bias.

Prospective longitudinal studies improve temporal ordering. In Constance Hammen and colleagues' two-year follow-up, childhood-adversity histories predicted depressive reactions at lower subsequent psychological stress levels. Measuring events and symptoms over time made this more informative than asking affected people retrospectively why they became ill. Yet adversity was not randomized, and histories may be measured imperfectly. Temporal precedence is necessary for the proposed direction of influence, but does not remove familial liability, prior symptoms or unmeasured social circumstances as competing explanations.^[ref]

Stronger observational designs make their counterfactual comparison explicit. A natural experiment exploits an external change that alters exposure without being produced by the same individual characteristics that usually determine it. E. Jane Costello and colleagues observed children before and after an income supplement associated with a casino opening. Comparing developmental changes across differently affected families strengthened the social-causation interpretation for particular behavioral outcomes. It did not randomize poverty, and concurrent community changes or selection into an income-defined subgroup remain possible alternatives.^[ref]

A difference-in-differences analysis formalizes such reasoning as the exposed group's change minus the comparison group's change. Its causal interpretation requires a credible untreated trend comparison, no differential concurrent change that explains the effect, and careful attention to anticipation and changes in sample composition. Merely measuring before and after a policy is not sufficient. Examining pre-intervention trends can expose some problems but cannot prove that every counterfactual assumption is true.

A randomized controlled trial offers another route by breaking systematic baseline links between allocation and measured or unmeasured causes. The foster-care offer in the Bucharest Early Intervention Project is an example of ethically intervening to improve a harmful setting, rather than deliberately assigning children to initial deprivation. Under suitable follow-up and analysis, differences between allocated groups estimate the effect of offering that intervention. Nonadherence, placement changes and attrition still matter. An intention-to-treat analysis retains the allocation comparison; simply regrouping children by the care they eventually received can reintroduce selection.^[ref]

Even a successful trial does not identify the causal contribution of every component. A foster-care package changes several experiences simultaneously. A coping course may alter attention, expectations, peer contact and behavior. To identify a mediator, it is necessary to consider confounding of the mediator–outcome relationship and its temporal ordering, not only whether the treatment changes both mediator and outcome. Conversely, a null intervention can reflect inadequate delivery, insufficient contrast or the wrong developmental timing; it need not prove that the proposed risk factor is irrelevant under every possible intervention.

Genetically informed studies address another set of alternatives. Comparing differently exposed identical twins can reduce confounding by inherited sequence and shared family background. However, exposure differences can arise from nonshared antecedents that also affect disorder, and within-pair measurement error can be substantial. Family and adoption designs are similarly informative without making every remaining environmental association causal. Molecular associations can indicate inherited liability, but linkage disequilibrium and population stratification separate an associated marker from a demonstrated mechanism.

Mendelian randomization uses genetic variants as instruments for an exposure, requiring relevant instruments, independence from exposure–outcome confounders and an exclusion restriction. The design can be useful when its assumptions are credible. It is not a shortcut for every social risk factor: horizontal pleiotropy, parental genetic effects and ancestry structure can create misleading estimates. A genetic score associated with stressful experiences does not necessarily act only through those experiences. This is a methodological distinction, not evidence that any particular untested exposure is causal.

Animal experiments can manipulate mechanisms and timing more tightly. Karen J. Parker and colleagues randomized young squirrel monkeys to intermittent separation experiences or a comparison condition and later tested responses in a novel setting. This supports causal conclusions about that rearing contrast and those measured responses. It does not directly estimate the effect of childhood adversity on human psychiatric diagnoses: species, development, psychological stressor meaning and outcomes differ.^[ref]

The strongest conclusion is obtained when these designs converge despite their different weaknesses, with sensitivity analyses and transparent outcome definitions. A causal claim should specify the contrast it establishes and the alternatives it has not excluded. Prospective timing, externally driven exposure changes, randomization, within-family controls and mechanistic experiments together can provide much stronger evidence than any isolated risk correlation, while still leaving uncertainty about transport to another population or developmental stage.

Test metabolic response and verified exposure, rather than using body weight as the sole definition of efficacy. Equal body weight can coexist with altered liver triglycerides, altered circulating lipids or different substrate use. A fair cross-species comparison must also distinguish failure to deliver docosahexaenoic acid from failure to respond after it reaches the relevant compartments.

Parallel randomized interventions. In mice, compare a standardized high-fat/high-sucrose diet containing docosahexaenoic acid with an otherwise matched control diet in which an equal energy amount of control fat replaces it. Keep total fat, sugar, protein, micronutrients and energy density constant; measure actual food intake. Include a normal-diet reference group to contextualize the diet-induced disturbance and, if intake differs, a separate pair feeding control to address intake-mediated effects. The pair-fed group answers a different question from the freely fed control, so it should not replace it. Standardize age and housing, include both sexes with a planned analysis, and randomize across cages and processing batches. If diet is assigned by cage, replicate and analyze the cage-level assignment rather than treating all cage-mates as independent treatment allocations.

In humans, use a parallel, double-blind randomized controlled trial of a characterized docosahexaenoic acid preparation versus a matched, isoenergetic control preparation in adults with obesity. Choose the exposure under an approved clinical protocol, maintain background diet and activity as consistently as practical, and record medication, alcohol and other supplement use. Avoid combining one arm with an unbalanced weight-loss programme. The control oil is a defined comparator with its own possible biology, not an assumed metabolically inert substance. Block randomization on important baseline factors and blind clinical assessors and laboratory staff.

Choose dose and duration to compare achieved exposure, not simply the same milligrams per kilogram across species. Analyze the administered diets and preparations for fatty-acid composition and oxidation. Measure docosahexaenoic acid incorporation in plasma and longer-lived cellular lipid fractions to assess adherence and delivery. A predeclared study duration of roughly twelve weeks in humans, with a comparable mouse time course chosen for its biology, is an example design rather than a claim that identical calendar time implies identical metabolic exposure.

Samples and timing. Collect standardized fasting plasma before treatment and at early, intermediate and final visits, for example weeks 2, 6 and 12 in humans. In a subset, add a standardized-meal time course before and after intervention to measure postprandial trajectories rather than only a fasting endpoint. Record fasting duration, collection time, handling delay and recent diet. Collect urine for complementary small-molecule measurements. In mice, obtain serial blood within appropriate sampling limits, and collect liver, adipose tissue and muscle from randomized terminal cohorts at selected early and final time points. These terminal tissues are from different animals and must not be analyzed as within-animal repeated measurements.

Use comparable plasma fractions in both species for the primary cross-species analysis. Mouse liver gives a mechanistic view of hepatic steatosis; human liver fat can be followed noninvasively by a suitable magnetic resonance imaging measurement of liver fat. Do not require research liver biopsies solely to make the matrices match. Optional tissue collection must have separate justification. Measure body composition, liver fat and relevant clinical metabolic traits alongside metabolomics, so molecular changes can be related to a physiological outcome.

Analytical measurements. Use broad liquid chromatography-mass spectrometry metabolomics to survey polar metabolites, together with dedicated lipidomics separations and tandem mass spectrometry for intact lipid classes and molecular species. Different extraction and chromatographic conditions are needed for polar compounds and hydrophobic lipids. Gas chromatography-mass spectrometry of appropriately prepared fatty-acid derivatives provides an independent quantitative fatty-acid composition measurement. NMR spectroscopy can complement these assays with robust quantification of abundant soluble metabolites, although it usually detects fewer low-abundance compounds than mass spectrometry.

Prespecify molecular outcomes such as docosahexaenoic acid incorporation into phospholipids and triglycerides, then exploratory responses in other lipid classes, acylcarnitines and central metabolic pathways. A possible response is incorporation of more highly unsaturated lipid species without weight loss; reduced liver fat or altered postprandial handling could then reveal a metabolic effect missed by body weight. Conversely, altered precursor pools do not themselves prove increased pathway flux. Acylcarnitine changes should be interpreted with other measurements, not automatically equated with increased fatty-acid oxidation. These are hypotheses to test, not assumed treatment outcomes.

Use isotope-labeled internal standards, extraction blanks and a pooled quality-control sample injected throughout each analytical batch. Randomize sample order while balancing species, arm and time; include shared reference material across batches. Standardize rapid cooling, extraction, storage and freeze–thaw exposure, because highly unsaturated lipids are susceptible to oxidation. Verify key metabolite identities with retention behaviour, fragmentation and authentic standards where available. An accurate mass alone does not uniquely establish a lipid's double-bond positions or distinguish all structural isomers.

Statistical plan. Power the study for a limited set of primary biochemical or physiological endpoints, using anticipated variance and independent treatment units. Keep discovery lipidomics separate from confirmatory endpoints. Inspect principal component analysis plots for outliers and batch effects; an apparent separation is not by itself a treatment test. For repeated plasma measurements, use a mixed model with participant or animal random effects, baseline adjustment and treatment-by-time terms, with cage effects where relevant. Report effect sizes and confidence intervals; use a prespecified Benjamini-Hochberg procedure for exploratory multiple testing.

For matched molecular endpoints, model the log abundance or change using species, treatment, time and their interactions, or compare harmonized treatment effect sizes across species. A species-by-treatment interaction addresses differing responses. A significant result in mice and a nonsignificant result in humans does not establish that the responses differ. Differences in achieved exposure, sampled tissue, starting diet or baseline disease can still explain an apparent interaction; document these before attributing the difference to species physiology. Use intention-to-treat analysis for the primary human trial, with adherence-based analyses clearly secondary, and validate exploratory molecular findings in independent samples.

Ethics. Obtain informed consent and independent ethical review, explain uncertainty about benefit, protect identifiable molecular and clinical data, monitor adverse events and allow withdrawal. Do not induce obesity or require a harmful diet merely to mimic the mouse model, and do not withhold established care. Minimize blood and tissue sampling and justify any optional biopsy separately. Animal work likewise needs justified numbers, humane endpoints and refinement of sampling. The design should answer the cross-species question with the least invasive measurements that can distinguish exposure, molecular response and physiology.

A treatment consequence is not interchangeable with a baseline covariate in an intention-to-treat analysis. Let randomized $Z$ be independent of $U,\epsilon$, and let actual intervention use be $D=Z+U$, with $Y=D+\epsilon$ and independent centered errors. The assignment changes the mean outcome by one. But the conditional expectation $\mathbb{E}[Y\mid Z,D]=D$ has coefficient zero on $Z$. Thus adjustment for the post-randomization variable $D$ changes the estimand even in a simple identified linear regression.

Treatment contamination occurs when participants in one arm of a randomized controlled trial receive an intervention assigned to another arm. This is distinct from contamination in robust estimation. The intention-to-treat analysis still compares randomized assignments, but intervention receipt becomes less separated between the arms, often diluting the assignment effect. Receipt-based comparisons can introduce confounding because receipt need not be randomized.